IMBRUVICA 140 mg, film-coated tablet 30 tablets
Active ingredients: Ibrutinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMBRUVICA 140 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) PVC polychlortrifluoroéthylène aluminium unidose(s) de 1 comprimé(s)
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- 100 %
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Macroglobulinémie de Waldenström chez les patients chez lesquels un autre traitement a déjà été essayé<br>- Lymphome à cellules du manteau en rechute ou résistant à d'autres traitement <br>- Leucémie lymphoïde chronique (LLC), en respectant certains critères précisément définis. ; JOURNAL OFFICIEL ; 01/08/17
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Feb 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64209404CIP73018248CIP133400930182482Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IBRUTINIBcomprimé | 140 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.